Pediatrix Medical Group, Inc.(MD)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #1,196 of 2,962 stocksTOP 50%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
MD Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Pediatrix Medical Group, Inc. (MD), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MD at 56.2/100 on a 32-signal composite quality model, placing it at rank #1,196 of 2,962 stocks — the top half of the AI-ranked universe. MD scores in the top quartile across balance sheet strength (80.9). Areas of concern include revenue growth (20.7), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), Pediatrix Medical Group, Inc. reports quarterly revenue of $487.8M, net income of $39.8M, an operating margin of 11.7%. Top institutional holders of MD by reported 13-F value include BlackRock, VANGUARD PORTFOLIO MANAGEMENT, DIMENSIONAL FUND ADVISORS, based on the most recent SEC filings. MD trades on the NYSE exchange and files with the SEC under CIK 893949. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Pediatrix Medical Group, Inc. directly from SEC EDGAR. Pediatrix Medical Group, Inc.'s 13F Pro composite quality score has ranged between 55 and 63 since 2026, currently 56.2 — a declining long-term trajectory across 48 quarterly and live scoring snapshots.
Revenue
Q2 2026
$487.8M
Net Income
Q2 2026
$39.8M
Operating Margin
Q2 2026
11.7%
ROIC
Q2 2026
15.5%
D/E Ratio
Q2 2026
0.66
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
-4.9% YoYNet Income
+266.9% YoYOperating Income
+403.9% YoYEPS (Diluted)
+263.0% YoYTotal Assets
+4.4% YoYTotal Debt
-5.4% YoYOp. Cash Flow
+31.2% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $1.91B -4.9% | $2.01B +0.9% | $1.99B +1.1% | $1.97B +3.2% | $1.91B +10.2% | $1.73B |
| Net Income | $165.4M +266.9% | $-99.1M -64.0% | $-60.4M -191.1% | $66.3M -49.3% | $131.0M +116.4% | $-796.5M |
| Operating Income | $208.8M +403.9% | $-68.7M -1038.6% | $7.3M -95.8% | $172.7M -14.9% | $202.9M +106.8% | $98.1M |
| EPS (Diluted) | $1.94 +263.0% | $-1.19 -63.0% | $-0.73 -192.4% | $0.79 -48.4% | $1.53 +116.0% | $-9.55 |
| Total Assets | $2.25B +4.4% | $2.15B -3.0% | $2.22B -5.5% | $2.35B -13.8% | $2.72B -18.7% | $3.35B |
| Total Debt | $597.3M -5.4% | $631.7M -0.8% | $637.1M -2.3% | $652.1M -34.3% | $992.2M -41.6% | $1.70B |
| Operating Cash Flow | $271.1M +31.2% | $206.6M +50.4% | $137.3M -17.7% | $166.9M +117.5% | $76.7M -62.5% | $204.6M |
Get alerted when MD's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Pediatrix Medical Group, Inc. including:
Top Institutional Holders of MD
BlackRock, Inc.
$347.4M13,714,275 shVANGUARD PORTFOLIO MANAGEMENT LLC
$151.6M5,985,147 shDIMENSIONAL FUND ADVISORS LP
$106.9M4,220,311 shVANGUARD CAPITAL MANAGEMENT LLC
$91.7M3,620,040 shSTATE STREET CORP
$89.5M3,533,248 shVICTORY CAPITAL MANAGEMENT INC
$86.6M3,416,913 shWASATCH ADVISORS LP
$63.3M2,498,884 shGEODE CAPITAL MANAGEMENT, LLC
$56.4M2,226,028 shAMERICAN CENTURY COMPANIES INC
$55.5M2,192,017 shFULLER & THALER ASSET MANAGEMENT, INC.
$43.6M1,721,451 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $347.4M | 13,714,275 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $151.6M | 5,985,147 |
| DIMENSIONAL FUND ADVISORS LP | $106.9M | 4,220,311 |
| VANGUARD CAPITAL MANAGEMENT LLC | $91.7M | 3,620,040 |
| STATE STREET CORP | $89.5M | 3,533,248 |
| VICTORY CAPITAL MANAGEMENT INC | $86.6M | 3,416,913 |
| WASATCH ADVISORS LP | $63.3M | 2,498,884 |
| GEODE CAPITAL MANAGEMENT, LLC | $56.4M | 2,226,028 |
| AMERICAN CENTURY COMPANIES INC | $55.5M | 2,192,017 |
| FULLER & THALER ASSET MANAGEMENT, INC. | $43.6M | 1,721,451 |
Companies Similar to MD
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Prestige Consumer Healthcare Inc.
Ingevity Corp
HEALTHCARE SERVICES GROUP INC
Guardian Pharmacy Services, Inc.
Addus HomeCare Corp
COLLEGIUM PHARMACEUTICAL, INC
Bioventus Inc.
Amneal Pharmaceuticals, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put MD on your watchlist
Track score changes the day Pediatrix Medical Group, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is MD a good stock to buy?
13F Pro's AI-powered analysis of Pediatrix Medical Group, Inc. (MD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MD are available on the MD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. MD is classified as a mid company.
Which hedge funds own MD?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Pediatrix Medical Group, Inc.'s investment landscape.